Although both the treatment protocol and the administered activity in the present study were equal to the prostate cancer treatment schedules, response rates were less favourable: one out of six patients obtained a partial response on 68Ga-PSMA-PET/CT, and one patient had stable disease of lung metastases. The gene discussed is FOLH1; the disease is prostate cancer.